Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

79 results about "Antithrombins" patented technology

Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins.

Anticoagulant fusion protein anchored to cell membrane

The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
Owner:IMPERIAL INNOVATIONS LTD

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerizazion.
Owner:ORESTE PASQUA +1

Lubricious or/and wettable or/and Anti-thrombin elastomeric gland materials in luer activated devices

An elastomeric gland is provided for a luer activating device (LAD). and comprises a unique lubricant and / or wetting agent and / or anti-clotting agent incorporated into the elastomer gland during raw material formulation, calendar blending / molding / curing to deliver the surface lubricity and / or wettability and / or avoid slit plane re-knitting and / or gland induced valve stick down of such devices Functional additive chemistries are selected in terms of generated functional performance level, thermal stability against processing, molecular migratability, molecular weight and elastomer substrate of interest. These additives could include lubricants like chemically modified silicone oils and / or wetting agents like silicone-based surfactant. Elastomer gland with wetting agent would ease fluid path priming and minimize micro air bubble adherence to gland surface. Additives may also include anti-clotting agents intended to reduce potential for clot formation within the fluid path and interstitial space of the valve during blood sampling and infusion.
Owner:BAXTER INT INC +1

Method for preparing antithrombin

The invention provides a method for preparing antithrombin, which comprises the following steps of: (a) precipitation and dissolution; (b) PEG precipitation; (c) virus inactivation; (e) demodulation; (h) adsorption of residual heparin; (i) virus inactivation; and (j) bacterium removal sub-packing and freeze-drying. Through the invention, the hard silica gel matrix (HeparinHyperD) with higher chemical stability is subjected to heparin affinity chromatography; the matrix has better ability against alkali resistance, and is more suitable for needs of industrial production; and the inventor improves the purification technology and the virus inactivation removal and conducts organic combination to expect deep comprehensive utilization of blood plasma and improve the effectiveness and safety of the AT-III preparation, thereby providing a new option to clinical treatment.
Owner:CHENGDU RONGSHENG PHARMA

Method of producing recombinant antithrombin III composition

The present invention provides a process for producing an antithrombin III composition comprising an antithrombin III molecule having complex type N-glycoside-linked sugar chains, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains.
Owner:KYOWA HAKKO KIRIN CO LTD

Compositions and methods for cell transplantation

InactiveUS20130302291A1Easy to returnEffective and safe combinationOrganic active ingredientsBiocideBiologyBivalirudin
The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin.
Owner:UNIVERSITE CATHOLIQUE DE LOUVAIN

Novel medicament for treating cardio-cerebrovascular diseases and preparation method

InactiveCN102793734AAchieving a good effect of treating both symptoms and root causesFully absorbedAnthropod material medical ingredientsMetabolism disorderDiseaseFreeze-drying
The invention relates to a novel medicament for treating the cardio-cerebrovascular diseases and a preparation method and belongs to the technical field of preparation of the novel medicament for treating the cardio-cerebrovascular diseases. According to the invention, blood-sucking leeches, panax pseudoginseng and earthworm are used as raw materials. According to the invention, by a special preparation process of carrying out liquid nitrogen flash freezing, low-temperature superfine grinding and freeze drying before sterilization on the raw materials, the grinding fineness can reach 1 to 10 micrometers, the active ingredients of the blood-sucking leeches can be stored to the greatest extent, the active ingredients can be sufficiently adsorbed by a patient, and the novel medicament has comprehensive effects of promoting circulation, removing stasis, resisting to coagulation, reducing the pressure, lowering lipid, resisting to platelet aggregation and dissolving thrombi and is safe and reliable to take. The invention solves the problems that an existing medicament which uses leeches as the raw materials and is used for treating the cardio-cerebrovascular diseases adopts non blood-sucking leeches as the medicine and adopts a conventional grinding method, so that the antithrombase effect is poor and the curative effect is influenced; and enteric capsules only adopt the single medicine of blood-sucking leech and have poor effects of reducing the pressure, lowering the lipid and dissolving the thrombi and the preparation process ensures the active ingredients of the leeches not to be completely stored and is unbeneficial for a patient to adsorb the active ingredients.
Owner:龚元

Light-emitting diode (LED) phototherapy oxygenation type haemodialysis machine

The invention discloses a light-emitting diode (LED) phototherapy oxygenation type haemodialysis machine, which is applied to haemodialysis ultra-filtration for treating diseases of acute renal failure, chronic renal failure, uremia, hypertension, arteriosclerosis, blood hyperviscosity, histanoxia and the like and belongs to the field of medical instruments. The LED phototherapy oxygenation type haemodialysis machine mainly comprises an LED phototherapy oxygenation part device, a blood extracorporeal circulation pipeline, a dialysate supply water pipeline and a circuit controlled by a microcomputer. The machine is characterized in that: the LED phototherapy oxygenation part device is embedded into an arterial cup clamper and a dialyser clamper of the blood extracorporeal circulation pipeline by a plurality of small-sized LED multi-wavelength penetration nails. In the process of haemodialysis, part of or all of lamps in the LED phototherapy oxygenation device can operate according to a specific situation for carrying out on-line irritation on blood in the circulation pipeline by utilizing a principle of strong penetrating power of LED multi-wavelength, so that blood circulation can be improved, agglutination of erythrocytes, platelet aggregation and blood viscosity are reduced, the flow rate of blood is improved, antithrombin is activated, the content of thrombin is reduced, coagulation and hemostasis mechanisms are adjusted, and the aim of treatment is achieved.
Owner:鲁广洲

Protective agent of human antithrombin preparation in freezing and drying process

The invention discloses a protective agent of human antithrombin preparation in freezing and drying process. According to the protective agent, a protective agent solution is prepared from one of solute sucrose, amino acid or salt of the amino acid by using deionized water, wherein the amino acid is lysine or hydrochloride in the salt of the lysine, or tyrosine or one of the salts in the tyrosine, or aspartic acid or one of the salts in the aspartic acid; one of the solutes is prepared into a solution by using deionized water so as to obtain the protective agent; the protective agent is added before the human antithrombin preparation is frozen and dried, the inactivation of the main antithrombin ingredient in the preparation in the freezing and drying process is effectively prevented, the activity of the antithrombin is protected, and the antithrombin has better forming appearance and redissolving clarity of the preparation after being frozen and dried.
Owner:GUIZHOU TAIBANG BIOLOGICAL PROD

Reagent and method for measuring thrombin-antithrombin complex

Provided is a reagent for assaying a thrombin-antithrombin complex (TAT) in a blood sample from a subject by latex agglutination assay. The reagent includes a polycation. As a result, TAT complexes can be precisely assayed while circumventing the effect of heparin. The polycation is, for example, hexadimethrine bromide, chitosans, modified dextran, aminodextran, hydroxymethyl cellulose trimethylamine, lysozyme, spermine, spermidine, polylysine, polyarginine, polyornithine, protamine sulfate, hydroxyethyl cellulose trimethylamine, heparin-binding protein, polyallylamine, polyallylamine hydrochloride, poly(diallyl dialkyl amine), polyamideamine, polyamine, polyvinylbenzyltrimethylammonium chloride, polydiallyldimethylammonium chloride, polyethyleneimine, polypropyleneimine, polypropylethyleneimine, polyimidazoline, polyvinylamine, polyvinyl pyridine, poly(acrylamide/methacryloxypropyltrimethylammonium bromide), poly(diaryldimethylammonium chloride/N-isopropylacrylamide), poly(dimethylaminoethyl acrylate/acrylamide), poly(dimethylaminoethyl methacrylate), polydimethylaminoepichlorohydrin, polyethyleneiminoepichlorohydrin, polymethacryloxyethyl-trimethylammonium bromide, hydroxypropylmethacryloyloxyethyl dimethyl ammonium chloride, poly(methyldiethylaminoethylmethacrylate/acrylamide), poly(methyl/guanidine), polymethylvinylpyridinium bromide, poly(vinylpyrrolidone-dimethylaminoethyl methacrylate), or polyvinylmethylpyridinium bromide.
Owner:MITSUBISHI CHEM MEDIENCE

Instrument for capturing free thrombi

The purpose of the present invention is to provide an instrument for capturing free thrombi, which can inhibit a blood coagulation reaction at a primary hemostasis stage in which platelet is involved or a coagulated thrombi formation stage in which a blood coagulation factor is involved, whereby it becomes possible to secure the capture of free thrombi and to prolong the usable time of the instrument. The present invention provides: an instrument for capturing free thrombi, in which a compound having an anti-thrombin capability is immobilized on the surface thereof; and a method for capturing free thrombi, which comprises capturing free thrombi in blood in vivo using the instrument for capturing free thrombi.
Owner:井上宽治 +1

Protein chip for combined detection of multiple thrombus markers

The invention discloses a protein chip for combined detection of multiple thrombus markers. A preparation method of the protein chip comprises the following steps: (1) black slide pretreatment; (2) antibody solution sample application; (3) a sealing process; and preparation of the protein chip. The protein chip is used for detecting concentrations of various thrombus markers, preventing and reducing thrombus risks and guiding thrombus treatment. The product disclosed by the invention is a protein chip diagnostic kit comprising six indexes of TAT (thrombin-antithrombin complex), PIC (plasmin-alpha2 anti-plasminogen complex), tPAIC (tissue-type plasminogen activator-plasminogen activation inhibition complex), TM (thrombomodulin), FDP (fibrinogen degradation product) and DD (D-dimer). The indexes are detected by using a protein chip technology for the first time, and the method has the advantages of quickness, high efficiency, simplicity, convenience, low cost and the like.
Owner:江苏三联生物工程股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products